Compare EDUC & LNAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EDUC | LNAI |
|---|---|---|
| Founded | 1965 | N/A |
| Country | United States | United States |
| Employees | N/A | 29 |
| Industry | Consumer Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 10.7M | 11.9M |
| IPO Year | 1995 | N/A |
| Metric | EDUC | LNAI |
|---|---|---|
| Price | $1.35 | $0.32 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 11.7K | ★ 38.8M |
| Earning Date | 05-18-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $34,191,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $2.14 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.01 | $0.15 |
| 52 Week High | $1.84 | $1.66 |
| Indicator | EDUC | LNAI |
|---|---|---|
| Relative Strength Index (RSI) | 55.32 | 43.28 |
| Support Level | $1.35 | $0.15 |
| Resistance Level | $1.37 | $0.99 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 81.20 | 6.15 |
Educational Development Corp is the United States trade publisher of the line of educational children's books produced in the United Kingdom. Its business activity functions with two reportable segments: PaperPie and Publishing. The Publishing Division segment markets its products to retail accounts, which include books, school supplies, toy and gift stores and museums, through commissioned sales representatives, trade and specialty wholesalers and an internal telesales group.
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.